OSTEOSARCOMA RECURRENT
Clinical trials for OSTEOSARCOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OSTEOSARCOMA RECURRENT trials appear
Sign up with your email to follow new studies for OSTEOSARCOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests an experimental oral drug called AMXT 1501 combined with another drug, eflornithine (DFMO), in children and young adults up to age 21 with certain cancers like neuroblastoma, brain tumors, and sarcomas. The first part finds the safest dose, and the second part ch…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 17, 2026 06:42 UTC
-
Can a drug keep relapsed bone cancers at bay?
Disease control Recruiting nowThis study tests whether a drug called DFMO can help prevent cancer from coming back in children and young adults with relapsed Ewing sarcoma or osteosarcoma who have finished all other treatments and currently show no signs of cancer. The main goal is to see if giving DFMO is pr…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated May 17, 2026 06:40 UTC
-
New hope for kids and adults with returning bone cancer?
Disease control Recruiting nowThis early-phase trial tests a new drug called tegavivint combined with the chemotherapy gemcitabine in people whose osteosarcoma (a type of bone cancer) has returned or not responded to treatment. The main goal is to find the safest dose of the combination and see if it can cont…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 17, 2026 06:38 UTC
-
Promising combo therapy for childhood cancers enters human trials
Disease control Recruiting nowThis study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…
Matched conditions: OSTEOSARCOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated May 17, 2026 06:23 UTC